A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients with Hypertension

Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Nov 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying new treatment options for people with essential hypertension, which is a condition where blood pressure is consistently too high. Specifically, researchers are comparing the effectiveness and safety of a combination of two medications (DWC202405/DWC202313 and DWC202314) to see if it works better than just the single combination therapy (DWC202405/DWC202313). The trial is currently looking for participants who are age 18 and older and have high blood pressure that isn’t well controlled with their current treatment.

If you decide to take part, you will undergo a screening process to check your blood pressure. To be eligible, your average systolic blood pressure (the top number) should be between 140 and 180 mmHg, and your average diastolic blood pressure (the bottom number) should be less than 110 mmHg. Participants will take the assigned treatment and will be monitored to see how well it works and if there are any side effects. This trial is important because it could lead to better options for managing high blood pressure for those who need additional help.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Average systolic blood pressure (MSSBP) and average diastolic blood pressure (MSDBP) measured at the time of screening meet the following criteria (a) If antihypertensive drugs are being administered: 140 mmHg ≤ MSSBP \< 180 mmHg and MSDBP \< 110 mmHg However, the criteria of 130 mmHg ≤ MSSBP \< 180 mmHg and MSDBP \< 110 mmHg are applied to patients with the following diseases.
• Exclusion Criteria:
• • If the blood pressure measured at the time of screening and randomization is MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg
• • Those whose blood pressure differences measured on both arms at the time of screening are MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg